Zander, Thomas

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,789

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 504

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 197

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

Scheffler, M., Bos, M., Gardizi, M., König, K., Michels, S., Fassunke, J., Heydt, C., Künstlinger, H., Ihle, M., Ueckeroth, F., et al. (2015) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 147

PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations

Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 111

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 73

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

Hescheler, D. A., Plum, P. S., Zander, T., Quaas, A., Korenkov, M., Gassa, A., Michel, M., Bruns, C. J., & Alakus, H. (2020) · Gastric Cancer

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 12

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

Van Cutsem, E., Yaeger, R., Delord, J.-P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., et al. (2023) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3